Table 1.
Single-target clinical trials
| Target | Disease | Agent | Phase | Clinical Trial Number | Status/Results |
|---|---|---|---|---|---|
| EGFR | PDAC | Erlotinib | II | NCT01608841 | 51 |
| EGFR | PDAC | Afatnib | II | NCT02451553 | Active |
| GRB2 | Solid tumor | BP1001 | I | NCT04196257 | Recruiting |
| SHP2 | Solid tumor | HBI2376 | I | NCT05163028 | Recruiting |
| KRAS-G12C | Solid tumor | sotorasib | III | NCT03600883 | 44 |
| KRAS | PDAC | Rat sarcoma KRAS vaccine | I | NCT05013216 | Active |
| KRAS | PDAC | mDC318 KRAS vaccine | I | NCT03608631 | Recruiting |
| KRAS-G12D | PDAC | exosome-KRAS(G12D)-siRNA | I | NCT03608631 | Recruiting |
| KRAS | Solid tumor | MRTX849 | I、II | NCT03785249 | Recruiting |
| BRAF | PDAC | Vemurafenib | II | NCT05068757 | Recruiting |
| MEK | Solid tumor | Pimasertib | I、II | NCT01016483 | 52 |
| MEK | Solid tumor | GSK1120212 | II | NCT01231581 | 53 |
| ERK | Solid tumor | Ulixertinib | I | NCT04566393 | Active |
| mTOR | PDAC | Sirolimus | I、II | NCT03662412 | Recruiting |